KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessShares Issued
Ratios

Jazz Pharmaceuticals (JAZZ) Short-Term Debt repayments (2016 - 2017)

Historic Short-Term Debt repayments for Jazz Pharmaceuticals (JAZZ) over the last 3 years, with Q3 2017 value amounting to $500.0 million.

  • Jazz Pharmaceuticals' Short-Term Debt repayments changed N/A to $500.0 million in Q3 2017 from the same period last year, while for Jun 2018 it was $500.0 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $500.0 million for FY2020, which is N/A changed from last year.
  • Per Jazz Pharmaceuticals' latest filing, its Short-Term Debt repayments stood at $500.0 million for Q3 2017.
  • Jazz Pharmaceuticals' Short-Term Debt repayments' 5-year high stood at $500.0 million during Q3 2017, with a 5-year trough of $80.0 million in Q4 2015.
  • In the last 3 years, Jazz Pharmaceuticals' Short-Term Debt repayments had a median value of $150.0 million in 2016 and averaged $216.0 million.
  • The largest annual percentage gain for Jazz Pharmaceuticals' Short-Term Debt repayments in the last 5 years was 8750.0% (2016), contrasted with its biggest fall of 8750.0% (2016).
  • Over the past 3 years, Jazz Pharmaceuticals' Short-Term Debt repayments (Quarter) stood at $80.0 million in 2015, then surged by 87.5% to $150.0 million in 2016, then skyrocketed by 233.33% to $500.0 million in 2017.
  • Its Short-Term Debt repayments stands at $500.0 million for Q3 2017, versus $200.0 million for Q2 2017 and $150.0 million for Q1 2017.